2022), and an effect of a bispecific CD73xEGFR antibody in vitro and in mice (Ploeg et al. 2023). These results together with clinical programs testing anti‐CD73 antibody oleclumab treatment in NSCLC, alone or combined with immune checkpoint inhibitors (Bendell et al. 2023, Barlesi et al. 2024, Besse et al. 2024), suggests that an interesting way to continue would be to study these treatments together with osimertinib in EGFR T790M positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.